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Summary The use of cytotoxic drug vincristine (VCR) is limited by the occurrence of peripheral neuropathy.
A neurotrophic ACTH(4-9) analogue, ORG 2766, is being studied for its protective effect. Possible
modulatory effects of ORG 2766 on tumour cell growth and interference with the cytotoxic efficacy of VCR
were studied in two human lymphoma cell lines, U937 and U715. The effects of ORG 2766 on cell growth and
survival and on VCR-mediated cytotoxicity were investigated using two MTT-based assays to study direct
cytotoxic effects and to assess residual growth after pretreatment. Treatment with ORG 2766 alone had no
effect on cell growth and survival. Neither did this drug affect VCR cytotoxicity. However, after 96 h
pretreatment with ORG 2766 and a culture period of 7 days, a reduction in residual growth and a potentiation
of VCR-induced inhibition of growth capacity was observed in U715 cells, and to some extent also in U937
cells. It is concluded that ORG 2766 has no stimulatory effects on tumour growth and does not negatively
interfere with VCR-mediated cytotoxicity. Rather it enhances the cytostatic effect of VCR. It is suggested that
ORG 2766 can safely be used in clinical trials investigating the ability of ORG 2766 to counteract VCR-
induced neurotoxicity.
Vincristine (VCR) is a vinca alkaloid extracted from the
periwinkle plant Catharantus roseus. This agent has con-
siderable cytotoxic effects in acute lymphoblastic leukaemia,
Hodgkin's lymphoma, non-Hodgkin lymphoma, sarcoma,
childhood tumours and small-cell carcinoma of the lung
(Bender & Chabner, 1982; Legha, 1986). Although the
precise mechanism of action has not been elucidated, anti-
tumour activity seems to be mainly based on the binding of
vinca alkaloids to tubulin, thus interfering with the micro-
tubules of the mitotic spindle apparatus. Because of disrup-
tion of the spindle apparatus, mitosis will be arrested. The
effects of VCR on microtubules in neural tissue, the so-called
neural tubules, will impede axonal transport processes by the
formation of paracrystals (Bunt, 1973; Donoso et al., 1977;
Muller et al., 1988; Takanari et al., 1990). This is considered
to be the main factor responsible for the induction of
peripheral neuropathy by VCR, a side-effect which is dose-
limiting (Rosenthal & Kaufman, 1974; Legha, 1986).
Whether particular drugs, e.g. pyridoxine and folinic acid,
possess the potential to counteract VCR-induced neuropathy
has been studied (Jackson et al., 1986a,b). Apart from a
once-reported beneficial effect of glutamic acid, no significant
counteraction has been established (Jackson et al., 1988).
When severe neuropathy develops, VCR treatment has to be
postponed or the dose has to be reduced.
ORG 2766, an ACTH(4-9) analogue, has been the subject
of research for many years because of its neurotrophic pro-
perties. In animal studies, ORG 2766 enhances recovery in
rats with crush lesions of peripheral nerves (De Koning &
Gispen, 1987; Gerritsen van der Hoop et al., 1988a). Con-
comitant treatment with this neuropeptide also prevents
cisplatin-induced neuropathy in rats (De Koning et al., 1987;
Gerritsen van der Hoop et al., 1988b). In the pond snail
Lymnaea stagnalis, an increase in the number ofmicrotubules
in the axons of the cerebral commissure has been found after
treatment of isolated cerebral ganglia with ORG 2766
(Muller et al., 1992). Furthermore, in this model, glial cells
seem to be activated, as indicated by a change in the
chromatin pattern in the nuclei and an increase in the
amount of glial tissue (Muller et al., 1993). Moreover, co-
treatment of neurons of L. stagnalis with VCR and ORG
2766 results in a decrease in the severity of neurotoxic effects
as compared with treatment with VCR alone (Muller et al.,
1991).
In ovarian cancer patients, cisplatin-induced neuropathy
was prevented or attenuated by ORG 2766 (Gerritsen van
der Hoop et al., 1990). In a recent pilot study in patients
with malignant lymphoma, we demonstrated an ameliorating
effect of ORG 2766 on VCR neurotoxicity (Van Kooten et
al., 1992). This was reason to start a more extensive study
involving a larger group of patients with malignant lym-
phoma.
The obvious beneficial effects of ORG 2766 on the
development of drug-induced neurotoxicity raises questions
about possible stimulatory effects on tumour cell growth and
interference with the anti-tumour activity of cytostatic com-
pounds. Administration of ORG 2766 to mice bearing
implanted tumour cells from a human tumour cell line had
no effect on the anti-tumour activity of cisplatin. Further-
more, no influence of ORG 2766 on tumour response to
cisplatin was found in the previously mentioned study on
patients suffering from ovarian cancer (Gerritsen van der
Hoop et al., 1990). Finally, in the pilot study of Van Kooten
et al. (1992) no indications for an interference of ORG 2766
with the cytotoxic action of VCR was observed. However,
only a small number of patients was included in this
study.
To our knowledge, no study has been performed to inves-
tigate any possible stimulatory effects of ORG 2766 on
tumour cells or interference with VCR cytotoxicity in vitro.
Since the cytotoxic action of VCR is mainly based on inhibi-
tion of the formation of microtubules, the recently observed
increase in the number of microtubules in nervous tissue of
L. stagnalis caused by ORG 2766 prompted us to study the
effects of this neuropeptide on VCR-mediated cytotoxic
activity. Therefore, the direct effects of ORG 2766 on cell
survival and VCR cytotoxicity and the residual growth after
pretreatment with these drugs were studied in two human
lymphoma cell lines, U937 and U715 (Nilsson & Sundstrom,
1974; Carlsson et al., 1983).
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Materials and methods
Cells and culture
U937 cells (a human histiocytic lymphoma cell line, pur-
chased from ATCC, Rockville, MD, USA) and U715 cells [a
human B-lymphocytic lymphoma cell line, generously pro-
vided by K. Nilsson (Nilsson & Sundstrom, 1974)] were
cultured routinely in RPMI-1640 L-glutamine (Gibco), supp-
lemented with 100Umlm' penicillin, 100tLgml-l strep-
tomycin and 10% heat-inactivated fetal calf serum (FCS,
Gibco). This medium is subsequently referred to as standard
medium. Cells were incubated at 37°C, in 5% carbon dioxide
and 90% relative humidity, and regularly checked to be
negative for mycoplasma, using a Gen Prob Kit (Lab Service,
Benelux). Cell viability (trypan blue dye exclusion) was
always >95%. Under these conditions, doubling rates of
U937 cells were 35-40 h and of U715 cells 25-30 h.
Drugs
Vincristine sulphate was kindly provided by Eli Lilly
(Research Laboratories, Indianapolis, IN, USA). The con-
centrations used were based on clinically obtained serum
values. The concentrations of ORG 2766, kindly provided by
Organon International (Oss, The Netherlands), were based
on results obtained with in vitro studies in L. stagnalis and on
serum values from healthy volunteers (see Discussion). The
drugs were supplied in pure form without any preservatives.
No drug vehicle had to be used and the drugs could easily be
dissolved in standard medium. The same medium was used
for the controls. Solutions were freshly prepared before use
and filtered through a 0.22jim filter (Millipore).
Study design to assess the direct effects ofORG 2766 on cell
survival and on VCR-mediated cytotoxicity by an MTT-based
cytotoxicity assay
U937 and U715 cells were seeded at a final concentration of
6,000 cells per well and 8,000 cells per well respectively, in a
total volume of 100 LI, in a 96 well round-bottomed mic-
rotitre plate (Greiner, 650180), for experiments which
required incubations of 24 and 48 h. For incubation of 72
and 96 h, 3,000 cells per well and 4,000 cells per well of U937
and U715 were seeded respectively. All experiments were
performed in triplicate. Cells were seeded in a 80I.I volume
in standard medium. Drugs were added in a constant volume
of 20gLl in experiments on the influence of either ORG 2766
or VCR on cell survival. VCR was added in a concentration
range of 10-" to 4 x 10- M by seven serial 4-fold dilutions.
ORG 2766 was added in a range of 10-'0M to 10-4M by
seven serial 10-fold dilutions. Untreated control wells were
filled with 20,il standard medium. To study the possible
influence of ORG 2766 on VCR-mediated cytotoxicity, each
drug was added in a volume of 10 lI. In these experiments
ORG 2766 was used in two concentrations, 10- M and
10-8 M, combined with a similar VCR concentration range as
described above. The two concentrations of ORG 2766 were
based on previous data (Muller et al., 1992) and on data
obtained in the present study. To measure cell survival, the
cell number was quantified spectrophotometrically by an
MTT assay.
Study design to assess residual growth after pretreatment with
ORG 2766 and/or VCR by an MTT-basedgrowth assay
To quantify residual growth of U937 and U715 cells after
incubations with ORG 2766, VCR or a combination of these
drugs, experiments were performed as follows. Cells at a
concentration of 0.1 x 106 cellsml' (U715) and 0.5 x 106
cells ml-' (U937) were preincubated for 48 and 96 h in cul-
ture flasks (Nunclon) in 5 ml of standard medium. ORG
2766 10- M or 10-8 M, with or without VCR, was added in
a volume of 100jil. VCR was added in a volume of 100 AlI to
achieve the final concentration, which was based on the LD50,
as measured in the experiments described above. For U937
cells this VCR concentration was 12 x 10-10 M and
8 x 100- M for 48 and 96 h respectively. For U715 cells the
LDm was 3 x 10-8 M and 2 x 10-9 M for 48 and 96 h respec-
tively. After 48 or 96 h of incubation, cells were washed in
Hanks' balanced salt solution containing 0.1% bovine serum
albumin (Boseral 20T, Organon Teknika). Cells were checked
for viability and adjusted to 8 x 103 viable cells ml-' (U937)
and 12 x I03 viable cells ml-' (U715) in semisolid culture
medium. These concentrations showed optimal cell culture
requirements. Cell suspension was seeded in 6-fold in a con-
stant volume of 100 ftl per well, in a 96 well flat-bottomed
microtitre plate (Greiner, 655180). After culturing for 7 days,
residual growth was assessed spectrophotometrically as de-
scribed below.
MTT-based cytotoxicity assay
The MTT assay was performed as described by Mosmann
(1983) and modified by Alley et al. (1988) and Van de
Loosdrecht et al. (1991). MTT [(3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide, Sigma M2128] was dis-
solved in sterile saline at 5mgml-l and filtered through a
0.22 Am filter (Millipore) to remove formazan crystals and
stored at -20°C in the dark. After incubation with the
various drugs in a 96-well round-bottomed microtitre plate,
cell survival was measured. A 10lI aliquot of MTT was
added to each well for 4 h at 37°C, as described previously
(Van de Loosdrecht et al., 1991). Plates were then centrifuged
for 10min at 275g. The supernatant was gently aspirated
without disturbing the precipitate. To dissolve the formazan
crystals, 150,ul per well DMSO (Baker, The Netherlands)
and 25 JAl per well glycine buffer (0.1 M glycine, pH 10.5)
were added. Complete solubilisation was achieved by
vigorously shaking on a microplate shaker for 15 min.
Optical density was read on a spectrophotometer (Titertek
Multiscan MCC 340, Flow Laboratories), at a wavelength of
540 nm. Survival was expressed as percentage of untreated
controls.
MTT-basedgrowth assay
The MTT-based growth assay was performed as we described
recently (Schweitzer et al., 1993). The semisolid medium con-
sisted of RPMI-1640 2 mM L-glutamine, FCS 10% (v/v),
methylcellulose 0.6% (w/v) (Dow Chemical, Germany),
penicillin 100Umlm', streptomycin 100tLgml', human
transferrin 7.7 x 10-M (Behring TRE-05), GM-CSF
100 U ml-1 (Behring), IL-3 1,000 U ml-' (Behring; specific
activity IL-3: 6 x 10' Umg-' protein) and glutathione 1%
(v/v) (Boehringer Mannheim, Germany). Cell suspension was
seeded in a 96 well flat-bottomed microtitre plate (Greiner).
After a culture period of 7 days under standard culture
conditions, 10 il of MTT was added to each well for 4h.
After the incubation time, the complete contents of each well
were transferred to a corresponding well in a round-
bottomed plate (Greiner). The original wells were washed
with RPMI-1640, after which complete removal of formazan
crystals was confirmed by inverted microscopy. Formazan
was solubilised in a similar fashion as described above for the
MTT assay. Residual growth capacity was expressed as
percentage of untreated controls.
Statistics
All data are the results of three experiments. They were
analysed by the two-tailed Student's t-test (P<0.05). Data
are expressed as mean ± standard error of the mean (s.e.m.).
Results
Influence ofORG 2766 and VCR on cell survival
The survival of U937 cells after continuous exposure to ORG
2766 in a concentration range of 10- M to 10-4 M forEFFECTS OF ORG 2766 ON VCR CYTOTOXICITY 499
24-96 h is presented in Figure 1. Neither significant
cytotoxic nor stimulatory effects were observed. Similar
results were obtained with U715 cells (data not shown).
The constant exposure of U937 and U715 lymphoma cell
line to different concentrations of VCR revealed typically
plateau-forming survival curves. Increasing the concentration
of VCR or the duration of exposure from 24 to 96 h resulted
in progressive cell kill. This is shown for 48 and 96 h in
Figures 2 and 3 for U937 and U715 cells respectively.
Influence ofORG 2766 on VCR-mediated cytotoxicity
Figures 2 and 3 also show the effects of ORG 2766 on
VCR-mediated cytotoxicity. Two concentrations of ORG
2766 (10-5 M and 10-8 M) were studied (see Discussion).
Neither potentiation nor inhibition of VCR-mediated
cytotoxicity was observed after co-treatment with ORG 2766
in both U937 and U715 cells. As can be deduced from the
figures, the LD50 for U937 cells was 12 x 10`0M and
8 x 1010 M after 48 and 96 h of incubation respectively. For
U715 cells, the LD50 was 3 x 10-8 M and 2 x 10- M after 48
and 96 h of incubation respectively.
Residual growth of U937 and U715 cells after pretreatment
with ORG 2766 with and without VCR
To study residual growth capacity, cells were exposed to
10-5 M and 10-8 M ORG 2766, with or without VCR, for 48
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Figure 1 Survival of U937 cells under constant exposure to
ORG 2766 in different concentrations for 24 ( _ ), 48 ( M ),
72 ( M ) and 96 ( =l ) h. Survival is expressed as percentage of
untreated controls. Values are means of three experiments ±
s.e.m.
120-
100-
a
40-
20-
-.'Z Al..
46Zh
96hs*
1.~~~'z
; l
and 96 h. The VCR concentration used was based on the
LD50 as found in liquid culture (see above). After these
preincubation periods, cells were cultured for 7 days as des-
cribed in Materials and methods.
Figure 4 shows the residual growth of U937 cells after 48
and 96 h pretreatment. ORG 2766 did not significantly
influence the growth capacity of these cells. However, there
was a slight, although not statistically significant, potentia-
tion of VCR-mediated cytotoxicity after 48 h, which was
even more pronounced after 96 h pretreatment.
The residual growth of U715 cells after 48 and 96 h
pretreatment is shown in Figure 5. The residual growth
activity after 48 h pretreatment with 10-5 M ORG 2766 had
decreased, although not statistically significantly, whereas no
potentiation of VCR-mediated cytotoxicity was observed.
After 96 h pretreatment, ORG 2766 (10-8 M) induced a
statistically significant reduction in residual growth as com-
pared with untreated controls (P<0.05). VCR-mediated
cytotoxicity was also significantly potentiated after this
period of pretreatment. A residual growth of 43.2 ± 6.3%
and 25.8 ± 2.2% was measured after treatment with VCR or
VCR with ORG 2766 (10-5M) respectively (P<0.05).
Discussion
In this report the effects of the ACTH(4-9) analogue ORG
2766 on cellular growth and survival and on VCR-mediated
cytotoxicity were studied in vitro in two well-known human
lymphoma cell lines, U937 and U715.
The use of ORG 2766, currently under investigation to
study its neuroprotective properties in VCR-induced
neuropathy, raises questions about possible effects on growth
and survival of tumour cells and interference with the efficacy
of anti-cancer drugs. For cisplatin a negative modulatory
effect with respect to the anti-tumour activity could already
be excluded (Gerritsen van der Hoop et al., 1988b, 1990). A
major point of study in this report was to investigate any
stimulatory effects of this trophic drug on lymphoma cells
and a negative interference with respect to VCR-mediated
cytotoxicity in order to determine whether ORG 2766 can be
safely co-administered to patients treated with VCR.
The VCR concentrations used in the present study are in
line with clinically obtained data (Bender et al., 1977; Jack-
son et al., 1981; Van Tellingen et al., 1992) and with earlier
described cytotoxic concentrations in vitro (Jackson &
Bender, 1979; Ferguson et al., 1984).
The concentrations of ORG 2766 were based on several
studies. In vitro studies with L. stagnalis revealed a maximal
increase in the number of microtubules in axons of the
central nervous system at a concentration as low as 10'8 M.
A concentration of 10-9 M had no effect, nor did higher
concentrations induce a larger increase in the number of
microtubules (Muller et al., 1992). In neuroblastoma cells,
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Figure 2 Survival curves of U937 cells under exposure to VCR
(0), VCR and 10-5M ORG 2766 (0) or VCR and 10-8M ORG
2766 (A). Exposure duration is 48 h (open symbols) and 96 h
(closed symbols) and cell survival is expressed as percentage of
untreated controls. Values are means of three experiments ±
s.e.m.
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Figure 3 Survival curves of U715 cells. For details see Figure
2.
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Figure 4 Residual growth capacity of U937 cells after 48 h (dark
bars) and 96 h (light bars) pretreatment and a culture period of 7
days. During pretreatment cells were exposed to 10-5 M and
10-8 M ORG 2766, with or without VCR (LD50). Growth
capacity is expressed as percentage of untreated controls. Values
are means of three experiments ± s.e.m. For 48 h and 96 h
treatments having the same symbols as superscript are not
significantly different; those with different superscripts are
(P<0.05).
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Figure 5 Residual growth capacity of U715 cells. For details see
Figure 4.
ORG 2766 induced an increase in protein synthesis. Also in
this study, a concentration of 10-8 M was the most effective
one (Murry et al., 1993). In healthy volunteers, serum values
of 5.6 ± 2.2 pmol ml-1 were obtained after a subcutaneous
injection of 2 mg, and this dose is used in ongoing clinical
trials. The bioavailability of ORG 2766 was ± 67%, and
peak levels were reached within 11 min. The drug was
eliminated from the blood with a half-time of approximately
85 min (Organon International, unpublished data).
In the U937 and U715 cell lines, VCR induced typically
plateau-forming survival curves, as has been described
previously (Brade, 1980). U715 cells appeared to be less
sensitive to VCR than U937 cells, as was shown by the fact
that a higher concentration was needed to obtain 50% cell
kill. Increased concentrations of VCR and prolonged incuba-
tion times with this drug increased the cytolytic effect, as has
also been described by Jackson and Bender (1979) and Brade
(1980). A discrepancy was found in the cytotoxic effect of
VCR between the standard cytotoxicity assay and the assay
to assess residual growth. In the latter assay, cells were
preincubated with the LD50 VCR concentration of the stan-
dard cytotoxicity assay. For 96 h pretreatment this concen-
tration was lower than for 48 h pretreatment. Although both
treatments led to 50% cell kill in the first series of experi-
ments, the residual growth was more seriously hampered
after the shorter period of pretreatment (48 h) with the
higher concentration of VCR. This might be related to a
greater sensitivity to VCR of early stages of cell division as
compared with the later stages, as has been described by
Yamashita et al. (1989). It can be assumed that during these
early stages more VCR is still present in the cells that have
been treated with the higher VCR concentration, since VCR
is intracellularly concentrated and retained tenaciously by
target cells (Gout et al., 1984). The higher VCR concentra-
tion in the experiments on 48 h pretreatment might be re-
sponsible for a more serious deterioration of residual
growth.
It can be concluded from the first series of experiments on
the effect of ORG 2766 alone that this drug, at concentra-
tions of 10`10M to 10'4 M and during various incubation
times, had no effect on cell survival. This seems plausible if
this peptide has only neurotrophic properties, i.e. if it exerts
no effect on other cell types, as has been suggested by Van
Huizen et al. (1991), who reported that ORG 2766 binds
almost exclusively to cell types with neuronal characteristics.
The experiments on the influence of ORG 2766 on VCR-
mediated cytotoxicity seem to confirm this hypothesis. The
survival curves of U937 and U715 cells obtained with VCR
alone were not different from those after co-treatment with
ORG 2766. However, in the experiments on residual growth
capacity, a statistically significant reduction in this capacity
was found in U715 lymphoma cells cultured for 7 days after
the longer period of pretreatment (96 h) with ORG 2766
(10`8 M). In these cells, ORG 2766 also significantly
(P<0.05) potentiated VCR cytotoxic action at 10-5 M after
96 h pretreatment. Also, with respect to U937 cells, there
were indications for such a potentiation, although no statis-
tically significant differences were obtained.
One might speculate on the mechanism underlying these
effects of ORG 2766. If it is assumed that the drug has
similar effects on the cell lines as on snail neurons, i.e. if it
stimulates microtubule formation, ORG 2766 might interfere
with spindle formation (this organelle consists largely of
microtubules) and hence with cell division. The ORG 2766
treatment might lead to an increased susceptibility of the
spindle to VCR, which would explain the increased cytotoxic
effect of this drug. Probably these effects only become appar-
ent in experiments of longer duration, i.e. in the experiments
on residual growth capacity, which lasted for 7 days, and not
in the shorter experiments on cell survival. It might be of
interest to investigate the interaction of other concentrations
of VCR and ORG 2766. However, the purpose of this study
was to investigate whether ORG 2766 can be safely admini-
stered to patients without having any adverse effects with
respect to tumour growth or VCR efficacy. For this reason
we intended to determine the effects of clinically achievable
concentrations of both drugs and in this study did not look
in more detail into the mechanism of the potentiation found.
More experiments are required to further elucidate the still
unknown mechanism of action of ORG 2766.
In the current chemotherapy schemes for Hodgkin and
non-Hodgkin malignant lymphomas (MOPP-ABV, COP,
CHOP), VCR is an important component of treatment. It is
given by intravenous bolus injection. No long-lasting
therapeutic levels are achieved in this way (Bender et al.,
1977). However, more frequent administration of VCR is not
feasible, because its use is limited by the occurrence of
peripheral neuropathy. The results of the present study
indicate that ORG 2766 can be given safely to patients in
trials without negatively modulating the anti-tumour activity
of the cytostatic agent and without stimulating tumour
growth. An effective agent, e.g. ORG 2766, counteracting the
dose-limiting side-effect can possibly lead to more frequent
administration, or to the use of higher dosages of the highly
effective anti-cancer drug, VCR.EFFECTS OF ORG 2766 ON VCR CYTOTOXICITY 501
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